Cheever, Martin A.

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 1,258

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchImmunotherapy and Immune Responses

Cited by 780

Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy

Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 396

Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 199